Schizophrenia

Neurology
204
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
23
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
48
4
37
3
59
53
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5100%
+ 225 programs with unclassified modality

On Market (23)

Approved therapies currently available

Alkermes
ARISTADAApproved
aripiprazole lauroxil
Alkermes
intramuscular2015
Alkermes
ARISTADA INITIO KITApproved
aripiprazole lauroxil
Alkermes
intramuscular2018
U
CLOZAPINEApproved
clozapine
Unknown Company
Atypical Antipsychotic [EPC]oral2024
U
ERZOFRIApproved
paliperidone palmitate
Unknown Company
intramuscular2024
VP
FANAPTApproved
iloperidone
Vanda Pharmaceuticals
Atypical Antipsychotic [EPC]oral2009
U
GALANTAMINE HYDROBROMIDEApproved
galantamine
Unknown Company
oral2011
U
ILOPERIDONEApproved
iloperidone
Unknown Company
oral2019
J&
INVEGA HAFYERAApproved
paliperidone palmitate
Johnson & Johnson
intramuscular2015
J&
INVEGA SUSTENNAApproved
paliperidone palmitate
Johnson & Johnson
intramuscular2009
J&
INVEGA TRINZAApproved
paliperidone palmitate
Johnson & Johnson
intramuscular2015
U
MEZOFYApproved
aripiprazole
Unknown Company
oral2025
U
OLANZAPINEApproved
olanzapine
Unknown Company
intramuscular2026
U
OPIPZAApproved
aripiprazole
Unknown Company
Atypical Antipsychotic [EPC]oral2024
U
QUETIAPINE FUMARATEApproved
quetiapine fumarate
Unknown Company
oral2017
J&
RISPERDALApproved
risperidone
Johnson & Johnson
Atypical Antipsychotic [EPC]oral1996
J&
RISPERDAL CONSTAApproved
risperidone
Johnson & Johnson
intramuscular2003
U
RISVANApproved
risperidone
Unknown Company
intramuscular2024
U
SEROQUELApproved
quetiapine
Unknown Company
oral1997
U
SEROQUEL XRApproved
quetiapine
Unknown Company
oral2007
U
VERSACLOZApproved
clozapine
Unknown Company
Atypical Antipsychotic [EPC]oral2013
AbbVie
VRAYLARApproved
cariprazine
AbbVie
Atypical Antipsychotic [EPC]oral2015
U
ZYPREXAApproved
olanzapine
Unknown Company
Atypical Antipsychotic [EPC]intramuscular2004
U
ZYPREXA ZYDISApproved
olanzapine
Unknown Company
Atypical Antipsychotic [EPC]oral2000

Competitive Landscape

46 companies ranked by most advanced pipeline stage

AstraZeneca
24 programs
1
6
3
Quetiapine XRPhase 41 trial
Seroquel and RisperidonePhase 41 trial
quetiapinePhase 41 trial
Olanzapine, risperidonePhase 31 trial
QuetiapinePhase 31 trial
+19 more programs
Active Trials
NCT01534936Completed2,153Est. Dec 2012
NCT01926340Completed178Est. Mar 2015
NCT00543088Completed250Est. Jun 2008
+21 more trials
Alkermes
AlkermesDUBLIN 4, Ireland
21 programs
4
2
11
3
Aripiprazole LauroxilPhase 41 trial
Aripiprazole LauroxilPhase 41 trial
Aripiprazole LauroxilPhase 41 trial
ALK3831Phase 31 trial
ALKS 3831Phase 31 trial
+16 more programs
Active Trials
NCT02804568CompletedEst. Aug 2016
NCT01493726CompletedEst. Jun 2013
NCT02320032CompletedEst. Apr 2016
+17 more trials
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
16 programs
6
1
5
4
AbilifyPhase 41 trial
Paliperidone ERPhase 41 trial
RISPERDAL CONSTA(Risperidone)Phase 41 trial
risperidone, quetiapinePhase 41 trial
Extended Release OROS® PaliperidonePhase 31 trial
+11 more programs
Active Trials
NCT00892541Completed30Est. Nov 2004
NCT00791284Completed20Est. Dec 2004
NCT00350467Completed288Est. Sep 2007
+29 more trials
Alliance Pharmaceuticals
1
2
1
2
2
Divalproex Sodium Extended-Release TabletsPhase 4
long-acting injectable risperidonePhase 41 trial
adjunctive treatment with buspironePhase 31 trial
creatinePhase 31 trial
GalantaminePhase 2/31 trial
+10 more programs
Active Trials
NCT01545999Active Not Recruiting72Est. Dec 2025
NCT00223535Completed40Est. Mar 2005
NCT01521026Completed69Est. Aug 2009
+12 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
12 programs
1
1
3
3
AripiprazolePhase 4Small Molecule1 trial
OlanzapinePhase 41 trial
olanzapine therapyPhase 41 trial
OlanzapinePhase 31 trial
OlanzapinePhase 31 trial
+7 more programs
Active Trials
NCT00400166Completed71Est. May 2009
NCT00661869Completed295Est. Jan 2008
NCT01088386Enrolling By Invitation4,000Est. Jun 2026
+9 more trials
VP
2
1
3
1
IloperidonePhase 41 trial
IloperidonePhase 31 trial
IloperidonePhase 31 trial
iloperidonePhase 31 trial
Iloperidone crystalline formulationPhase 1/2
+2 more programs
Active Trials
NCT04712734Completed42Est. Aug 2022
NCT06494397Completed26Est. Oct 2024
NCT00254202Completed593Est. Mar 2007
+3 more trials
M&
Merck & Co.RAHWAY, NJ
6 programs
1
1
1
Asenapine 10 mg daily in the eveningPhase 41 trial
MK-8435Phase 21 trial
MK-8189Phase 13 trials
Customized Adherence Enhancement for SchizophreniaN/A1 trial
Event-Related PotentialsN/A1 trial
+1 more programs
Active Trials
NCT06061952Completed36Est. Aug 2025
NCT04025502Completed161Est. Jan 2021
NCT00605995Terminated15Est. Aug 2011
+5 more trials
Sanofi
6 programs
6
AMISULPRIDEPhase 41 trial
AmisulpridePhase 41 trial
AmisulpridePhase 41 trial
AmisulpridePhase 41 trial
amisulpridePhase 41 trial
+1 more programs
Active Trials
NCT01795183Completed316Est. Dec 2013
NCT00419653Terminated19Est. Sep 2007
NCT00331981Completed138
+3 more trials
Abbott
AbbottABBOTT PARK, IL
4 programs
2
1
ValproatePhase 41 trial
ABT-126Phase 13 trials
SLV354Phase 11 trial
1 Hz rTMSN/A1 trial
Active Trials
NCT02242578Terminated2Est. Jun 2018
NCT01676935Terminated349Est. Mar 2014
NCT01043458Completed16
+3 more trials
Novartis
NovartisBASEL, Switzerland
4 programs
1
1
ClozapinePhase 43 trials
PEAR-004Phase 21 trial
Cross-Sectional Iloperidone IVGTTN/A1 trial
Event-Related PotentialsN/A
Active Trials
NCT01686815Completed37Est. May 2016
NCT03751280Completed112Est. Sep 2019
NCT00169026Terminated64Est. Jan 2004
+2 more trials
City Therapeutics
City TherapeuticsMA - Cambridge
4 programs
1
ClozapinePhase 41 trial
Narrative Enhancement and Cognitive TherapyN/A1 trial
Validating Three Common Occupational Therapy Assessments in Participants With SchizophreniaN/A1 trial
high-frequency transcranial alternating current stimulationN/A1 trial
Active Trials
NCT02421237CompletedEst. Jul 2018
NCT02930083CompletedEst. Dec 2015
NCT06470516RecruitingEst. Apr 2026
+1 more trials
Bristol Myers Squibb
4 programs
1
2
AripiprazolePhase 4Small Molecule1 trial
Xanomeline/TrospiumPhase 41 trial
KarXTPhase 11 trial
fMRIN/A1 trial
Active Trials
NCT00209027Terminated20Est. Apr 2011
NCT07061288Recruiting48Est. Oct 2027
NCT00177008Completed18Est. Jan 2007
+1 more trials
AbbVie
3 programs
2
1
1
CariprazinePhase 31 trial
ABT-126Phase 21 trial
EmraclidinePhase 21 trial
Active Trials
NCT01834638Terminated268Est. Nov 2014
NCT07145918Recruiting268Est. Feb 2028
NCT03593213Terminated587Est. Feb 2021
Astellas
AstellasChina - Shenyang
2 programs
1
ZotepinePhase 41 trial
Event-Related PotentialsN/A
Active Trials
NCT00418873Terminated39Est. Dec 2009
Verona Pharma
1 program
1
aripiprazolePhase 4Small Molecule1 trial
Active Trials
NCT00395915Unknown106Est. Dec 2009
Pfizer
16 programs
7
5
3
BifeprunoxPhase 31 trial
bifeprunoxPhase 31 trial
bifeprunox, olanzapinePhase 31 trial
BifeprunoxPhase 21 trial
BifeprunoxPhase 21 trial
+11 more programs
Active Trials
NCT00174200Completed20Est. May 2006
NCT01268124Completed56Est. Apr 2009
NCT00781794Withdrawn0Est. Aug 2009
+14 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
15 programs
4
6
BI 425809Phase 31 trial
Digital TherapeuticPhase 31 trial
IclepertinPhase 31 trial
IclepertinPhase 31 trial
IclepertinPhase 31 trial
+10 more programs
Active Trials
NCT06486948Completed58Est. Aug 2024
NCT06136936Completed53Est. Feb 2024
NCT05438160Completed48Est. Jul 2022
+12 more trials
Acadia Pharmaceuticals
8 programs
1
4
3
PimavanserinPhase 31 trial
PimavanserinPhase 31 trial
PimavanserinPhase 31 trial
ACP-103Phase 21 trial
ACP-104Phase 21 trial
+3 more programs
Active Trials
NCT00628420Completed45Est. Oct 2007
NCT00361166Completed400Est. Mar 2007
NCT00490516Completed247Est. Feb 2008
+5 more trials
Teva
6 programs
2
1
3
TV-44749Phase 31 trial
TV-46000Phase 31 trial
TV-46000Phase 31 trial
armodafinilPhase 21 trial
TV-44749Phase 11 trial
+1 more programs
Active Trials
NCT06315283Completed153Est. Sep 2025
NCT06253546Completed24Est. Jun 2025
NCT00487942Completed60Est. Dec 2007
+3 more trials
Takeda
5 programs
2
2
SPD489Phase 31 trial
SPD489 low dose rangePhase 31 trial
SPD489Phase 11 trial
TAK-058Phase 11 trial
Event-Related PotentialsN/A
Active Trials
NCT01457339Completed31Est. Jan 2012
NCT02614586Terminated11Est. Apr 2016
NCT01760993Terminated2Est. Apr 2013
+1 more trials
LP
LB PharmaceuticalsNEW YORK, NY
5 programs
2
1
2
LB-102Phase 31 trial
LB-102Phase 31 trial
LB-102Phase 21 trial
LB-102Phase 11 trial
LB-102Phase 11 trial
Active Trials
NCT04187560CompletedEst. Nov 2020
NCT04588129CompletedEst. Nov 2021
NCT06179108CompletedEst. Dec 2024
+2 more trials
Gedeon Richter
Gedeon RichterHungary - Budapest
5 programs
1
4
CariprazinePhase 31 trial
CariprazinePhase 31 trial
CariprazinePhase 31 trial
CariprazinePhase 31 trial
CariprazinePhase 21 trial
Active Trials
NCT00839852Completed97Est. Aug 2010
NCT01104779Completed446Est. Dec 2011
NCT03817502Recruiting330Est. Dec 2026
+2 more trials
Braeburn Pharmaceuticals
1
1
1
Risperidone implantPhase 31 trial
Risperidone ImplantPhase 21 trial
ATI-9242Phase 11 trial
Active Trials
NCT02824666Completed7Est. Nov 2016
NCT02658357Completed66Est. Aug 2017
NCT02773576Completed140Est. Sep 2017
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
2 programs
2
3-6mg QLM1016Phase 31 trial
Olanzapine-samidorphan;Phase 31 trial
Active Trials
NCT06799559Not Yet RecruitingEst. Dec 2026
NCT06649214Not Yet RecruitingEst. May 2026
Reviva Pharmaceuticals
1 program
1
BrilaroxazinePhase 31 trial
Active Trials
NCT05184335RecruitingEst. Feb 2025
Zai Lab
1 program
1
Xanomeline and Trospium Chloride CapsulesPhase 31 trial
Active Trials
NCT05919823Completed202Est. Dec 2024
BioLineRx
BioLineRxIsrael - Modi’in
4 programs
3
1
CYP-1020Phase 2/31 trial
BL - 1020Phase 21 trial
BL-1020Phase 21 trial
BL-1020Phase 21 trial
Active Trials
NCT00567710CompletedEst. Sep 2009
NCT00480571CompletedEst. Dec 2007
NCT00722176CompletedEst. Dec 2009
+1 more trials
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
1
CannabidiolPhase 21 trial
PergolideN/A1 trial
Active Trials
NCT01066403Completed28Est. Mar 2008
NCT02088060Terminated150Est. Sep 2024
Amgen
AmgenTHOUSAND OAKS, CA
2 programs
1
1
AMG 747Phase 21 trial
AMG 579Phase 11 trial
Active Trials
NCT01568203Terminated50Est. Jun 2012
NCT01568216Terminated121Est. Jun 2013
Newron Pharmaceuticals
2 programs
1
1
EvenamidePhase 21 trial
NW-3509aPhase 11 trial
Active Trials
NCT01955564CompletedEst. Feb 2015
NCT04461119CompletedEst. Mar 2021

+16 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Bristol Myers SquibbXanomeline/Trospium
AlkermesAripiprazole Lauroxil
Vanda PharmaceuticalsIloperidone
AlkermesAripiprazole Lauroxil
AlkermesAripiprazole Lauroxil
Johnson & Johnsonpaliperidone palmitate
Johnson & Johnsonpaliperidone palmitate
SanofiAMISULPRIDE
Johnson & Johnsonpaliperidone palmitate
Merck & Co.Asenapine 10 mg daily in the evening
Johnson & Johnsonpaliperidone palmitate
Johnson & JohnsonPaliperidone ER
Johnson & JohnsonPaliperidone ER
Johnson & JohnsonPaliperidone ER
AstraZenecaQuetiapine XR

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 7,083 patients across 50 trials

The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients

Phase 4Completed

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

Start: Apr 2025Est. completion: Nov 2026172 patients
Phase 4Not Yet Recruiting
NCT05662306AlkermesAripiprazole Lauroxil

C-Cog in Early Course Schizophrenia Study

Start: Jan 2024Est. completion: Mar 2025
Phase 4Terminated

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Start: May 2023Est. completion: Nov 2026100 patients
Phase 4Recruiting
NCT04203056AlkermesAripiprazole Lauroxil

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

Start: Dec 2019Est. completion: Oct 2022
Phase 4Terminated
NCT02634320AlkermesAripiprazole Lauroxil

A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia

Start: Dec 2015Est. completion: Jul 2017
Phase 4Completed
NCT01947803Johnson & Johnsonpaliperidone palmitate

A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia

Start: Sep 2013Est. completion: Mar 2015353 patients
Phase 4Completed
NCT01685931Johnson & Johnsonpaliperidone palmitate

A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics

Start: Nov 2012Est. completion: Dec 2014617 patients
Phase 4Completed

Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

Start: Nov 2012Est. completion: Dec 2013316 patients
Phase 4Completed
NCT01527305Johnson & Johnsonpaliperidone palmitate

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

Start: Jun 2012Est. completion: Dec 2013212 patients
Phase 4Completed
NCT01549041Merck & Co.Asenapine 10 mg daily in the evening

Once-Daily Asenapine for Schizophrenia

Start: Apr 2012Est. completion: Nov 201330 patients
Phase 4Completed
NCT01682161Johnson & Johnsonpaliperidone palmitate

A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

Start: Jan 2012Est. completion: Sep 2013154 patients
Phase 4Completed

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

Start: Aug 2011Est. completion: Nov 201611 patients
Phase 4Completed

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Start: Mar 2010Est. completion: Dec 201156 patients
Phase 4Completed

Efficacy and Safety of Paliperidone ER in First Episode Psychosis

Start: Feb 2010Est. completion: Feb 201375 patients
Phase 4Completed

Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

Start: Sep 2009Est. completion: Apr 201035 patients
Phase 4Completed

Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER

Start: Jul 2009Est. completion: Jul 201241 patients
Phase 4Completed

A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia

Start: May 2009Est. completion: Oct 201184 patients
Phase 4Completed

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Start: Jan 2009Est. completion: Mar 2010133 patients
Phase 4Completed

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity

Start: Dec 2008Est. completion: Dec 201017 patients
Phase 4Terminated
NCT00761670Sanofiamisulpride and risperidone

Efficacy Study on Cognitive Functions in Schizophrenic Patients

Start: Sep 2008Est. completion: Jan 201037 patients
Phase 4Completed

Symptomatic Remission and Social Function in Participants Treated With Paliperidone Extended Release (ER)

Start: Jul 2008Est. completion: Jun 2009480 patients
Phase 4Completed

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

Start: May 2008Est. completion: Apr 2009353 patients
Phase 4Completed

Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants

Start: Apr 2008Est. completion: Oct 2010387 patients
Phase 4Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Start: Mar 2008Est. completion: May 2009299 patients
Phase 4Completed

Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia

Start: Feb 2008Est. completion: Nov 200995 patients
Phase 4Completed

PaliperidoNe Extended-Release [ER] Dosing and Clinical Response in Acute Schizophrenia

Start: Feb 2008Est. completion: Jul 2010491 patients
Phase 4Completed

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

Start: Oct 2007Est. completion: Feb 2009121 patients
Phase 4Completed

An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment

Start: Jul 2007Est. completion: Jan 200931 patients
Phase 4Completed

Zotepine Versus Risperidone in Aggressive Schizophrenic Patients of Acute Ward

Start: Mar 2007Est. completion: Dec 200939 patients
Phase 4Terminated

Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia

Start: Sep 2006Est. completion: Dec 2009106 patients
Phase 4Unknown

Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet

Start: May 2006Est. completion: Sep 2007284 patients
Phase 4Completed
NCT00314327Alliance Pharmaceuticalslong-acting injectable risperidone

Optimizing Response in Psychosis Study

Start: Apr 2006Est. completion: Nov 20131 patients
Phase 4Terminated

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Start: Feb 2006Est. completion: Jan 2009355 patients
Phase 4Completed

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

Start: Dec 2005Est. completion: Jul 200716 patients
Phase 4Completed

SOLIACS: Solian Solution in the Acute Setting

Start: Jun 2005300 patients
Phase 4Completed

Amisulpride in Schizophrenic Acute Phase Patients

Start: May 200550 patients
Phase 4Completed

Valproate in Late Life Schizophrenia

Start: Nov 2004Est. completion: Nov 200620 patients
Phase 4Completed

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

Start: Mar 2004Est. completion: Jan 200718 patients
Phase 4Completed

Amisulpride in Schizophrenic Patients

Start: Feb 2004138 patients
Phase 4Completed
NCT00061802Johnson & Johnsonrisperidone, quetiapine

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

Start: Jun 2003Est. completion: Feb 2004225 patients
Phase 4Completed

Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy

Start: Jan 2003Est. completion: Sep 200719 patients
Phase 4Terminated
NCT00254241AstraZenecaSeroquel and Risperidone

Safety and Efficacy of Seroquel in First Episode Schizophrenia

Start: May 2002Est. completion: Jun 200680 patients
Phase 4Completed

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

Start: Aug 2001Est. completion: Jul 2002530 patients
Phase 4Completed

Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual

Start: Oct 2000Est. completion: Mar 2009
Phase 4Completed

Alcoholism and Schizophrenia: Effects of Clozapine

Start: May 1999Est. completion: Jan 200464 patients
Phase 4Terminated

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

Start: Mar 1996Est. completion: Oct 200332 patients
Phase 4Terminated

Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia

Start: Dec 1994Est. completion: Feb 200266 patients
Phase 4Terminated
NCT00297388Johnson & JohnsonRisperidone, long-acting injectable

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Est. completion: Sep 200440 patients
Phase 3Completed

52-week Open Label Safety-Tolerability Study

Start: Apr 2026Est. completion: Apr 2029
Phase 3Not Yet Recruiting

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

59 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 7,083 patients
30 companies competing in this space